172 related articles for article (PubMed ID: 26536105)
1. Demonstration of Therapeutic Equivalence of Fluconazole Generic Products in the Neutropenic Mouse Model of Disseminated Candidiasis.
Gonzalez JM; Rodriguez CA; Zuluaga AF; Agudelo M; Vesga O
PLoS One; 2015; 10(11):e0141872. PubMed ID: 26536105
[TBL] [Abstract][Full Text] [Related]
2. Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model.
Andes D; van Ogtrop M
Antimicrob Agents Chemother; 1999 Sep; 43(9):2116-20. PubMed ID: 10471550
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic equivalence requires pharmaceutical, pharmacokinetic, and pharmacodynamic identities: true bioequivalence of a generic product of intravenous metronidazole.
Agudelo M; Vesga O
Antimicrob Agents Chemother; 2012 May; 56(5):2659-65. PubMed ID: 22330928
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model.
Andes D; Stamsted T; Conklin R
Antimicrob Agents Chemother; 2001 Mar; 45(3):922-6. PubMed ID: 11181381
[TBL] [Abstract][Full Text] [Related]
5. Isavuconazole pharmacodynamic target determination for Candida species in an in vivo murine disseminated candidiasis model.
Lepak AJ; Marchillo K; VanHecker J; Diekema D; Andes DR
Antimicrob Agents Chemother; 2013 Nov; 57(11):5642-8. PubMed ID: 24002092
[TBL] [Abstract][Full Text] [Related]
6. In vivo characterization of the pharmacodynamics of flucytosine in a neutropenic murine disseminated candidiasis model.
Andes D; van Ogtrop M
Antimicrob Agents Chemother; 2000 Apr; 44(4):938-42. PubMed ID: 10722494
[TBL] [Abstract][Full Text] [Related]
7. Interaction between fluconazole and amphotericin B in mice with systemic infection due to fluconazole-susceptible or -resistant strains of Candida albicans.
Louie A; Banerjee P; Drusano GL; Shayegani M; Miller MH
Antimicrob Agents Chemother; 1999 Dec; 43(12):2841-7. PubMed ID: 10582869
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis.
Andes D; Marchillo K; Conklin R; Krishna G; Ezzet F; Cacciapuoti A; Loebenberg D
Antimicrob Agents Chemother; 2004 Jan; 48(1):137-42. PubMed ID: 14693531
[TBL] [Abstract][Full Text] [Related]
9.
Zhao M; Lepak AJ; VanScoy B; Bader JC; Marchillo K; Vanhecker J; Ambrose PG; Andes DR
Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29378706
[TBL] [Abstract][Full Text] [Related]
10. Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis.
Gumbo T; Drusano GL; Liu W; Ma L; Deziel MR; Drusano MF; Louie A
Antimicrob Agents Chemother; 2006 Nov; 50(11):3695-700. PubMed ID: 16954319
[TBL] [Abstract][Full Text] [Related]
11. Generic vancomycin products fail in vivo despite being pharmaceutical equivalents of the innovator.
Vesga O; Agudelo M; Salazar BE; Rodriguez CA; Zuluaga AF
Antimicrob Agents Chemother; 2010 Aug; 54(8):3271-9. PubMed ID: 20547818
[TBL] [Abstract][Full Text] [Related]
12. In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model.
Andes D; Marchillo K; Stamstad T; Conklin R
Antimicrob Agents Chemother; 2003 Oct; 47(10):3165-9. PubMed ID: 14506026
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of anidulafungin, caspofungin and fluconazole in the early phase of infection in a neutropenic murine invasive candidiasis model.
Krishnan-Natesan S; Manavathu EK; Cutright JL; Chandrasekar PH
Int J Antimicrob Agents; 2010 Jul; 36(1):33-6. PubMed ID: 20400270
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo comparison of the anti-staphylococcal efficacy of generic products and the innovator of oxacillin.
Rodriguez CA; Agudelo M; Zuluaga AF; Vesga O
BMC Infect Dis; 2010 Jun; 10():153. PubMed ID: 20525378
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models.
Andes D; Safdar N; Marchillo K; Conklin R
Antimicrob Agents Chemother; 2006 Feb; 50(2):674-84. PubMed ID: 16436726
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics/pharmacodynamic correlations of fluconazole in murine model of cryptococcosis.
Santos JR; César IC; Costa MC; Ribeiro NQ; Holanda RA; Ramos LH; Freitas GJ; Paixão TA; Pianetti GA; Santos DA
Eur J Pharm Sci; 2016 Sep; 92():235-43. PubMed ID: 27235581
[TBL] [Abstract][Full Text] [Related]
17. In vivo pharmacodynamics of a new triazole, ravuconazole, in a murine candidiasis model.
Andes D; Marchillo K; Stamstad T; Conklin R
Antimicrob Agents Chemother; 2003 Apr; 47(4):1193-9. PubMed ID: 12654646
[TBL] [Abstract][Full Text] [Related]
18. Nontherapeutic equivalence of a generic product of imipenem-cilastatin is caused more by chemical instability of the active pharmaceutical ingredient (imipenem) than by its substandard amount of cilastatin.
Agudelo M; Rodriguez CA; Zuluaga AF; Vesga O
PLoS One; 2019; 14(2):e0211096. PubMed ID: 30726248
[TBL] [Abstract][Full Text] [Related]
19. Enhanced pathogenicity of Candida albicans pre-treated with subinhibitory concentrations of fluconazole in a mouse model of disseminated candidiasis.
Navarathna DH; Hornby JM; Hoerrmann N; Parkhurst AM; Duhamel GE; Nickerson KW
J Antimicrob Chemother; 2005 Dec; 56(6):1156-9. PubMed ID: 16239285
[TBL] [Abstract][Full Text] [Related]
20. Effective concentration-based serum pharmacodynamics for antifungal azoles in a murine model of disseminated Candida albicans infection.
Maki K; Kaneko S
Eur J Drug Metab Pharmacokinet; 2013 Dec; 38(4):261-8. PubMed ID: 23539473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
